Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA 2020 |
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:brand |
gptkb:Trodelvy
|
| gptkbp:CASNumber |
1847461-43-1
|
| gptkbp:contains |
gptkb:SN-38
|
| gptkbp:developedBy |
gptkb:Gilead_Sciences
gptkb:Immunomedics |
| https://www.w3.org/2000/01/rdf-schema#label |
Sacituzumab govitecan
|
| gptkbp:indication |
metastatic urothelial carcinoma
metastatic triple-negative breast cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
Trop-2 protein
|
| gptkbp:mechanismOfAction |
delivers cytotoxic SN-38 to cancer cells
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
nausea diarrhea fatigue neutropenia |
| gptkbp:target |
gptkb:Trop-2
|
| gptkbp:UNII |
6Y7T8XW3F1
|
| gptkbp:usedFor |
gptkb:cancer
gptkb:triple-negative_breast_cancer urothelial cancer |
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|